Monitoring oral anticoagulation may require determination of single coagulation factor activities in patients with antiphospholipid syndrome.
We describe a 32-year-old man with secondary antiphospholipid syndrome (APS) who received oral anticoagulation with phenprocoumon after deep vein thrombosis. Conventional monitoring of oral anticoagulation by INR measurement was impaired by coagulation factor inhibition in vitro due to a strong lupus anticoagulant. The case illustrates that monitoring of oral anticoagulation may require determination of single coagulation factor activities in selected patients with APS.
Sucker
Christoph
C
Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Duesseldorf, Germany. sucker@med.uni-duesseldorf.de
Wenzel
Folker
F
Zotz
Rainer B
RB
Hetzel
Gerd R
GR
Scharf
Rüdiger E
RE
D000284:Administration, Oral; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D000925:Anticoagulants / Q000008:administration & dosage*; D016736:Antiphospholipid Syndrome / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000032:analysis*; D003951:Diagnostic Errors / Q000517:prevention & control*; D006801:Humans; D008297:Male; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D001779:Blood Coagulation Factors